About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 114 record(s)
Req # A-2021-10631
Provide the preparation documents (excluding PowerPoint), meeting summaries and emails related to meetings and communications between PMPRB executives and Amgen Canada Inc over planned reforms to the PMPRB Guidelines from June 1, 2019 to June 8, 2021. Do not include emails related to Zoom, Microsoft Teams or other such mediums for the purposes of conducting the meeting, only the content of the meeting itself.Organization: Patented Medicine Prices Review Board Canada
November 2021
Req # A-2021-10625
Provide the preparation documents (excluding PowerPoint), meeting summaries and emails related to meetings and communications between PMPRB executives and AbbVie over planned reforms to the PMPRB Guidelines from June 1, 2019 to June 7, 2021. Do not include emails related to Zoom, Microsoft Teams or other such mediums for the purposes of conducting the meeting, only the content of the meeting itself.Organization: Patented Medicine Prices Review Board Canada
October 2021
Req # A-2021-10630
Provide the preparation documents (excluding PowerPoint), meeting summaries and emails related to meetings and communications between PMPRB executives and the Canadian Cancer Society over planned reforms to the PMPRB Guidelines from June 1, 2019 to June 7, 2021. Do not include emails related to Zoom, Microsoft Teams or other such mediums for the purposes of conducting the meeting, only the content of the meeting itself.Organization: Patented Medicine Prices Review Board Canada
October 2021
Req # A-2021-10777
Copies of all communications between the PMPRB and the clerk of the Health Committee Jean-François Pagé from May 22, 2021 to June 11, 2021. Include internal emails between the PMPRB executives, particularly Tanya Potashnik, Douglas Clark, Mitchell Levine, and Isabel Jaen Raasch, regarding the communications from the clerk and the request to testify.Organization: Patented Medicine Prices Review Board Canada
October 2021
Req # A-2021-19384
The daily calendar of meetings, calls and other taskings for Tanya Potashnik from May 1, 2021 to October 14, 2021.Organization: Patented Medicine Prices Review Board Canada
October 2021
Req # ATI2022-003
Executive Compensation 2019 & 2020Organization: Business Development Bank of Canada
August 2021
Req # ATI2022-004
Venture Capital Catalyst Initiative Quarterly Report 2021Organization: Business Development Bank of Canada
August 2021
Req # A-2021-12332
Copies of all final IQVIA contracts and accompanying briefing materials, if applicable, for the contracts associated with the following procurement ID numbers: 160005 A3; 160005 A2; 160005 A5; 160005 A6; 160005 A7; 180030; 16NL008 A3; 16NL021 A4; 16NL021 A5; 16NL008 A4; 200051; 210020; 210021; and 200051 A1.Organization: Patented Medicine Prices Review Board Canada
August 2021
Req # A-2021-11082
Copies of all documents presented, and shared with participants related to the symposium organized by the PMPRB with academics during the week of May 31, 2021.Organization: Patented Medicine Prices Review Board Canada
July 2021
Req # A-2021-07238
Copies of all information, data, document, or correspondence concerning the PMPRB's classification of the following drug products: NOVORAPID and FIASP, each a product of NOVO NORDISK CANADA INC, a corporation located at 101-2476 Argentia Road, Mississauga, Ontario, Canada L5N 6M1, including but not limited to classifications based on drug product line extensions, similar chemical entities, comparable dosages, or a reasonable relationship between the two drugs, as well as any other analysis, comments, or information related to the classification of these two drugs.Organization: Patented Medicine Prices Review Board Canada
May 2021